Please login to the form below

Not currently logged in
Email:
Password:

Pfizer/ S-A vaccines halted in Japan

Separate vaccines from sanofi-aventis and Pfizer have had their use suspended in Japan following the deaths of four children

Separate vaccines from sanofi-aventis (S-A) and Pfizer have had their use suspended in Japan following the deaths of four children.

S-A's ActHIB, to protect against Haemophilus influenzae type b, and Pfizer's Prevenar to prevent against pneumococcal disease such as pneumonia and meningitis, have been suspended by Japan's Health Ministry while the causes of deaths of four inoculated children are investigated.

According to the Associated Press, four children, age 2 years old or under, died between March 2 and March 4, with the deaths occurring within a three day period of the vaccines administration.

Over one million children have been inoculated in Japan since ActHIB was launched in the country in December 2008 and Prevenar started to be used in 2009.

The suspension follows a 2009 incident where authorities suspended the use of a batch of Prevenar in the Netherlands after the deaths of three children inoculated with the vaccine.

Authorities later decided there was no correlation between the deaths and the vaccinations.

7th March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics